Clinical Staging and the Tendency of Malignant Pleural Mesotheliomas to Remain Localized
|
|
- Bonnie Pierce
- 6 years ago
- Views:
Transcription
1 Clinical Staging and the Tendency of Malignant Pleural Mesotheliomas to Remain Localized Russell J. Nauta, M.D., Robert T. Osteen, M.D., Karen H. Antman, M.D., and J. Kenneth Koster, M.D. ABSTRACT Thirty-two patients who had been treated for diffuse, malignant pleural mesotheliomas were retrospectively staged according to the system of Butchart. Nineteen of the 2 patients who were seen with disease confined to one hemithorax have died. Twelve patients died without progression to a higher clinical stage, and only 1 patient died of systemic metastases. Nineteen of the 32 patients died of local tumor invasion. Regimens containing Adriamycin (doxorubicin hydrochloride) appeared to prolong the survival of patients with epithelial-type tumors. Combination chemotherapy, designed to treat soft-tissue sarcomas, produced only partial responses in a small number of patients. Malignant pleural mesotheliomas arise from a tissue that is difficult to resect. Except for the diaphragmatic surface, the parietal pleura can be removed easily, but the lung must be sacrificed in order to resect the entire visceral pleura. Mesothelioma is a rare tumor. The clinical diagnosis is often confused with infections or metastases from other organs to the pleura. Histologically, the tumor may resemble a softtissue sarcoma or an adenocarcinoma. The rarity of the tumor, the difficulty of diagnosis, the poor prognosis, and the magnitude of the operation required to resect the entire pleura have made mesothelioma a challenge for modern oncology; palliative therapy has become the rule. The incidence of mesotheliomas appears to be increasing, probably as a result of increased exposure to asbestos during and after World War 1 [l-41. t has been predicted that the disease will increase during the next twenty to thirty years, until the effects of regulatory From the Department of Surgery, Brigham and Women s Hospital, and the Department of Medicine, Sidney Farber Cancer nstitute, Harvard Medical School, Boston, MA. Accepted for publication Nov 30, Address reprint requests to: Dr. Osteen, Brigham and Women s Hospital, 75 Francis St, Boston, MA legislation initiated in the early 190s are felt [l-51. The series of patients discussed here was reviewed to determine those features of the disease that might be important for planning therapy. Material and Methods The medical records and radiographs of 32 patients who were treated for diffuse, malignant pleural mesotheliomas at the Brigham and Women s Hospital and the Sidney Farber Cancer nstitute between February, 193, and February, 1980, were reviewed. Patients were classified retrospectively according to the staging system suggested by Butchart and associates []: Stage -tumor confined to the ipsilateral pleura, lung, and pericardium; Stage invasion of the chest wall and mediastinum; Stage 111-penetration of the diaphragm or lymph node metastases; Stage V-distant metastases. Hospital records were reviewed to evaluate the adequacy and effectiveness of diagnostic techniques, the staging system, the results of treatment, and the cause of death. Results Age and Sex Twenty-five men and 7 women were treated. The peak incidence of the disease was during the sixth decade of life. Men had occupational exposure to asbestos more frequently than did women, 0% and 28%, respectively. The median survival for the entire group was 12 months. The median survival for women was 34 months and for men, 10 months. The longer survival of women could not be explained by difference in stage at presentation, since the incidence of men and women in each stage was equal. n Stage, there were 10 men (40%) and 3 women (43%); in Stage 11, 10 men and 3 women; in Stage 111, 3 men (12%) and no women; and in Stage V, 2 men (8%) and 1 woman (14%) by The Society of Thoracic Surgeons
2 7 Nauta et al: Malignant Pleural Mesotheliomas Table 1. Relationship between Symptoms and Stage Stage Symptom 1 11 v Pain Dyspnea Pain + dyspnea anumbers are numbers of patients. hall patients had pain or dyspnea. Table 2. nitial Symptoms and Survival of Patients with Pleural Mesothelioma No. of Median survival Svmutom Patients (mo) Dyspnea Chest pain Dvsunea + uain 7 19 Symptoms All patients had pain or dyspnea, and some had both symptoms. Symptoms correlated with neither the stage of disease (Table 1) nor survival (Table 2). The slight differences in survival presented in Table 2 are not statistically significant, possibly because of the small number of patients in each category. Diagnostic Procedures Examination of pleural fluid samples from 2 patients yielded only two definitive diagnoses of mesothelioma. Two specimens were suggestive of mesothelioma and three were interpreted as malignant tumor. Four definitive diagnoses of mesothelioma were obtained by needle biopsy of the pleura. Twenty-four patients (75%) required open biopsies, including nineteen thoracotomies and two pericardial explorations, to establish the diagnosis. Two patients were thought to have soft-tissue sarcomas, until the diagnosis of mesothelioma was established at postmortem examination. Treatment was delayed for more than 2 months by uncertain diagnoses in 7 patients. n each instance, the delay was caused by inconclusive pathological findings and hesitation to subject the patient to an open biopsy. Histology The survival of patients in this series is compared in Table 3 with that in two other series according to histological subtype of the mesothelioma and the treatment given. Unlike the other two series shown in that table, our patients with epithelial tumors had a shorter survival than patients with the other two histological subtypes. Table 3. Survival by Histological Subtypes and Treatment in Three Series of Patients No. of Survival Series Histology Treatment Patients (mo) Brigham and Women s Hospital Resection 7 7 (median) + Sidney Farber Cancer rradiation 4 8, 8, 21, 145 nstitute [present report] + Resection 3 3, 14, 15 mixed + mixed rradiation 4 11,34,54,53 Memorial [9] Resection (median) rradiation 15 8 (median) Resection 1 11 (median) rradiation 7 9 (median) Newcastle upon Tyne [] Pleuro- 9 1 (median) pneumonectomy Pleuropneumonectomy 11 4 (median)
3 8 The Annals of Thoracic Surgery Vol34 No 1 July 1982 Table 4. Results of Various Therapies in 37 Patients Radiation Presenting Survival Operation Therapy Chemotherapy Stage Histology (mo) Pleurectomy Pleurectomy + chest wall resection x 3 Resection of pleural nodules + pericardiectomy + resection of chest wall nodule Decortication? Amount 3,000 Rads x 2 Gold seeds,000 Rads 1,500 Rads A, AD32 C, vinblastine Hy droxyurea mi tomycin-c, metho trexate, 5-fluorouracil, cis-platinum CCNU, methotrexate, Neocarcinostatin Cis-platinum, CCNU 1 1 v 1 1 V v 1 1 = not applicable; VCR = vincristen; A = Adriamycin (doxorubicin hydrochloride); = high-dose methotrexate + citrovonun factor; C = cyclophosphamide; CCNU = methyl chloroethyl cyclohexyl nitrosourea; D = dimethyltriazenoimidazole carboximide. *Alive. 14" * * * " 7* *
4 9 Nauta et al: Malignant Pleural Mesotheliomas Results of Therapy Patients were treated on an individual basis with various combinations of surgical intervention, radiation therapy, and cytotoxic drugs. No single treatment plan was followed. Operative intervention was confined to diagnostic biopsies and limited resections with no pleuropneumonectomies. Chemotherapy usually was given for gross disease, when the induction of complete remission was unlikely. The results of treatment are shown in Table 4. Eight patients received a chemotherapy regimen including Adriamycin (doxorubicin hydrochloride), 50 mg/m2 on day 1, cyclophosphamide, 00 mg/m2 on day 2, and imidazolcarboximide, 4,000 mg/m2 on days 1 and 2, repeated every 21 days. This regimen was begun in 1975, in the belief that mesotheliomas should be treated as if they were soft-tissue sarcomas. With that regimen, 3 patients experienced partial remission, 2 patients had progression, and 3 patients had stable disease for a brief period. The only suggestion of an effect on survival was seen in patients with epithelial tumors. Seven patients with epithelial tumors treated with Adriamycin-containing regimens had a median survival of 19 months, compared with a median survival of 7.5 months for the 12 patients with epithelial tumors who received either chemotherapy regimens that did not include Adriamycin or no chemotherapy at all. Stage Progression and Cause of Death Nineteen of the 2 patients who were seen with disease confined to one hemithorax (Stage or 11) died. Twelve died without clinical evidence of progression to a higher clinical stage, and only 1 patient died of systemic metastases. Progression from Stage, 11, or 11 to a higher stage was observed in 8 of 22 patients with Stage, 1 or 11 and epithelial or mixed histology and 3 of 7 patients with sarcomatous histology. Nineteen patients died of local tumor invasion causing respiratory obstruction and sepsis. Local tumor invasion was complicated by cardiac toxicity from Adriamycin in 1 patient, and radiation pneumonitis in another. Comment The preponderance of men and the longer survival of women in our series are striking. Estrogen-receptor protein was not measured in any of the tumors reported here nor has it been reported by other investigators. The tendency of men to receive a heavier occupational exposure to asbestos raises the possibility of a relationship between survival and dose of the inducing agent. The tendency of the tumor to remain local was demonstrated by the lack of progression in clinical stage and by the predominance of local complications as the cause of death. t is obvious that survival will not be improved unless more effective local control is obtained. The suggestion by Gottlieb and associates [A to treat mesothelioma as a type of soft-tissue sarcoma because of its mesenchymal origin is contradicted by the tendency of mesotheliomas to spread locally rather than to metastasize as do soft-tissue sarcomas. f local control improves, then metastatic disease may become a more predominant feature of the disease. n most instances, a thoracotomy will be required to establish the diagnosis. Since aggressive resections usually should be avoided for metastatic tumors and because the diagnosis of mesothelioma by frozen section may be difficult, it may be necessary to await interpretation of a permanent histological section before proceeding with definitive therapy at a second thoracotomy. Butchart and co-workers [1 reported the treatment of 29 patients with pleuropneumonectomy. Patients were selected for stage and histological subtype, with pleuropneumonectomy reserved for patients with epithelial disease classified as Stage. DeLaria and colleagues [81 reported 2 disease-free survivors at two and four years among 11 patients treated with radical extrapleural pneumonectomy. Both long-term survivors had epithelial-type tumors. Wanebo and associates [9] also reported longer survival of patients with epithelial tumors treated by resection compared with resected sarcomatous tumors. These reports suggest that resection may more favorably affect the course of epithelial tumors, but the number of patients treated by aggressive local therapy is still small and the natural histories of the different tumor subtypes are not known. The role of adjuvant radiation therapy is not well defined. n a nonrandomized series com-
5 70 The Annals of Thoracic Surgery Vol34 No 1 July 1982 paring operative intervention with radiation therapy, the survival of patients who had radiation treatment was inferior to that of patients who underwent resection [9]. External beam or implant radiation, appropriately combined with resection, may affect survival [lo, 111. The geometric - problem of treating the entire pleural surface with a uniform dose of radiation may impose practical limits on the use of radiation therapy. The partial responses seen in 5 of 13 patients treated with Adriamycin-containing regimens and the apparently improved survival of patients with the epithelial subtype who received Adriamycin both indicate that the drug has an effect on the tumor. The potential for improved survival, by means of surgical resection by pleuropneumonectomy, with radiation therapy to sites of residual disease combined with adjuvant Adriamycin, is under investigation at the Sidney Farber Cancer nstitute. References 1. Selikoff J, Churg J, Hammond FC: Relations between exposure to asbestos and mesothelioma. N Engl J Med 272:50, Selikoff J: Perspectives in preclinical management of cancer: initiation of a mesothelioma therapy research program. Mt Sinai J Med 44: 45, 1977 Manfredi F, Rosenbaum D, Childress RH: Diffuse malignant mesothelioma of the pleura. Am Rev Respir Dis 92:29, 195 Aisner J, Wiernik PH: Malignant mesothelioma: current status and future prospects. Chest 74:438, 1978 McDonald AD, Harper A, Attar OA, et al: Epidemiology of primary malignant mesothelial tumors in Canada. Cancer 2:914, 1970 Butchart EG, Ashcroft T, Barnsley WC, et al: Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 31:15, 197 Gottlieb JA, Baker LH, Quagliana JM, et al: Chemotherapy of sarcomas with a combination of Adriamycin and dimethyltriazenoimadazole carboxamide. Cancer 30:132, 1972 DeLaria GA, Jensik R, Faber LP, Kittle CF: Surgical management of malignant mesothelioma. Ann Thorac Surg 2:375, 1978 Wanebo HJ, Martini NM, Melamed MR, et al: Pleural mesothelioma. Cancer 38:2481, 197 Guttman RJ: Results of radiation therapy in patients with inoperable carcinoma of the lung whose status was established at exploratory thoracotomy. Am J Roentgen01 Radium Ther Nucl Med 93:99,195 Legha SS, Muggia FM: Therapeutic approaches in malignant mesothelioma. Cancer Treat Rev 4:13, 1977
Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationHigh-dose methotrexate in the treatment of malignant mesothelioma of
Br. J. Cancer (1992), 65, 956-960 '." Macmillan Press Br. Ltd., 1992 J. Cancer (1992), 65, 956-960 C Macmillan Press Ltd., High-dose methotrexate in the treatment of malignant mesothelioma of the pleura.
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationChemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma. A Review and Case Report
STATE OF THE ART: CONCISE REVIEW Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma A Review and Case Report Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA Introduction:
More informationChemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma
Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationTumour size as a prognostic factor after resection of lung carcinoma
Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationThe Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT
The Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT V. Lam, J. Brozik, A. J. Sharkey, A. Bajaj, D. T. Barnes Glenfield Hospital, Leicester, United
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationStandardizing surgical treatment in malignant pleural mesothelioma
Perspective Standardizing surgical treatment in malignant pleural mesothelioma David Rice University of Texas M.D. Anderson Cancer Center, Houston, TX, USA Corresponding to: David Rice. University of Texas
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe incidence of malignant pleural mesothelioma
Operation and Photodynamic Therapy for Pleural Mesothelioma: 6-Year Follow-up Thomas L. Moskal, MD, Thomas J. Dougherty, PhD, John D. Urschel, MD, Joseph G. Antkowiak, MD, Anne-Marie Regal, MD, Deborah
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationPleurectomy/decortication versus extrapleural pneumonectomy: a critical choice
Editorial Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice Pier Luigi Filosso, Francesco Guerrera, Paolo Olivo Lausi, Roberto Giobbe, Paraskevas Lyberis, Enrico Ruffini, Alberto
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationGeneral. for Thoracic Surgery GTS
General Thoracic Surgery Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma Terry T. Lee,
More informationTreatment of Inoperable Lung Carcinoma: A Combined Modality Approach
Treatment of Inoperable ung Carcinoma: A Combined Modality Approach Hiroshi Takita, M.D., Ariel C. Hollinshead, h.d., Donna J. Rizzo, R.N., Christine M. Kramer, M.S., Tah Y. Chen, M.D., Joginder N. Bhayana,
More informationLung cancer LUNG CANCER. Box 1 Clinical signs
22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationExtrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma?
Original Research Extrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma? PLEURA January-December 2015: 1-7 ª The Author(s) 2015 DOI: 10.1177/2373997515595219
More informationTherapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile?
Therapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile? Bram Balduyck, MD, Delphine Trousse, MD, Apostolos Nakas, MD, Antonio E. Martin-Ucar, MD, John Edwards, MD,
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationThe Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationUnderstanding Pleural Mesothelioma
Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationPleurectomy-decortication (P/D) was first popularized in
Technique of Pleurectomy and Decortication Andrew J. Kaufman, MD, and Raja M. Flores, MD Pleurectomy-decortication (P/D) was first popularized in the mid 1950s as a surgical method for treating entrapped
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationCollecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
More informationSystemic Management of Malignant Pleural Mesothelioma
ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital
More informationCauses of Treatment Failure and Death in Carcinoma of the Lung
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 201-207 Causes of Treatment Failure and Death in Carcinoma of the Lung JAMES D. COX, M.D.,a AND RAYMOND A. YESNER, M.D.b The Medical College of Wisconsin,
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLung Cancer 83 (2014) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:
Lung Cancer 83 (2014) 78 82 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Radical pleurectomy/decortication followed by high dose of radiation
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationInterstitial Irradiation for Unresectable Carcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 20 NUMBER 5 NOVEMBER 1975 Interstitial Irradiation for Unresectable Carcinoma
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationMalignant Pleural Mesothelioma COMBINED TREATMENT
Malignant Pleural Mesothelioma COMBINED TREATMENT Federica Grosso incidence Italy
More informationMESOTHELIAL TUMORS AND EXPOSURE TO ASBESTOS DUST
MESOTHELIAL TUMORS AND EXPOSURE TO ASBESTOS DUST W. Glyn Owen Pathology Department, Broadgreen Hospital, Liverpool, England The carcinogenic properties of asbestos have been recognized for several years,'.?
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationBoot Camp Case Scenarios
Boot Camp Case Scenarios Case Scenario 1 Patient is a 69-year-old white female. She presents with dyspnea on exertion, cough, and right rib pain. Patient is a smoker. 9/21/12 CT Chest FINDINGS: There is
More informationMammary Tumors. by Pamela A. Davol
Mammary Tumors by Pamela A. Davol Malignant tumors of the mammary glands occur with a higher incident than any other form of cancer in female dogs. Additionally, evidence suggests that females with benign
More informationThymic Tumors. Feiran Lou MD. MS. Kings County Hospital Department of Surgery
Thymic Tumors Feiran Lou MD. MS. Kings County Hospital Department of Surgery Case HPI 53 yo man referred from OSH for anterior mediastinal mass. Initially presented with leg weakness and back pain for
More informationTHORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
More informationClinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience
TURKISH JOURNAL of ONCOLOGY ORIGINAL ARTICLE Clinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience Şule KARABULUT GÜL, 1 Ahmet Fatih ORUÇ,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationMalignant pleural mesothelioma (MPM) is an aggressive
ORIGINAL ARTICLE Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung Emilio Minatel, MD,*
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationBiopsy Interpretation of Spindle cell proliferations of the Serosa
Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)
More informationTOP 10 Recent Advances in Veterinary Oncology 1. Six month chemo for lymphoma.1 2. FNA of non-palpable LN s.2
TOP 10 Recent Advances in Veterinary Oncology Philip J. Bergman DVM, MS, PhD Diplomate ACVIM, Oncology Chief Medical Officer BrightHeart Veterinary Centers 80 Business Park Drive, Suite 110, Armonk, NY
More informationProtocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Based on AJCC/UICC TNM, 7th edition Protocol web posting date: February 1, 2011 Procedures Resection Authors
More informationPrimary Rhabdomyosarcoma
CASE REPORTS Primary Rhabdomyosarcoma of the Bronchus Graham Fallon, M.D., Medad Schiller, M.D., and James W. Kilman, M.D. ABSTRACT A 6-year-old child with an unresectable rhabdomyosarcoma of the right
More informationAdjuvant therapy for thyroid cancer
Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationA case of giant benign localized fibrous tumor of the pleura
Turkish Journal of Cancer Vol.30 / No. 4/2000 A case of giant benign localized fibrous tumor of the pleura ALİ KEMAL UZUNLAR 1, MEHMET YALDIZ 1, İBRAHİM H. ÖZERCAN 2, FAHRİ YILMAZ 1, AKIN E. BALCI 3 1
More informationCollaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
More informationIntra-arterial chemotherapy for patients with
Annals of the Royal College of Surgeons of England (980) vol 62 ASPECTS OF TREATMENT* ntra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas Lord Smith of Marlow KBE MS PPRCS
More informationIntrarenal Extension. sinus
Intrarenal Extension into sinus Document Capsular Penetration sinus 16 Pediatric Renal Tumor Staging Stage I Limited to Kidney & Completely Resected Intact Renal Capsule No Previous Rupture or Biopsy Renal
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationHodgkin s Disease of the Mediastinum
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 3 NUMBER 4 APRIL 1967 Hodgkin s Disease of the Mediastinum William A. Burke,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationCitation for published version (APA): van Ruth, S. (2003). Hyperthermic intracavitary chemotherapy in abdomen and chest
UvADARE (Digital Academic Repository) Hyperthermic intracavitary chemotherapy in abdomen and chest van Ruth, S. Link to publication Citation for published version (APA): van Ruth, S. (2003). Hyperthermic
More informationMalignant pleural mesothelioma (MPM) affects nearly
ORIGINAL ARTICLE Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta, MD,* Lee M. Krug, MD, Benjamin Laser,
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationThe Learning Curve for Minimally Invasive Esophagectomy
The Learning Curve for Minimally Invasive Esophagectomy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J Swanson, M.D. Professor of Surgery Harvard
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationMalignant pleural mesothelioma (MPM) has a poor prognosis,
ORIGINAL ARTICLE Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP,* John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt,
More information